GlobeNewswire

Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy

Share
  • Label update includes data from four clinical studies including long-term safety and efficacy data across a broad Spinal Muscular Atrophy (SMA) population
  • Data from over 300 patients across a broad range of ages and types of Spinal Muscular Atrophy (SMA) who have received treatment for up to 5 years have been added to the label.  

BAAR, Switzerland, June 29, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced an update to the European label for nusinersen, incorporating longer-term data from four studies (NURTURE, EMBRACE, SHINE and CS3A). These studies, which looked at pre-symptomatic, infantile-onset and later-onset treatment, further confirm the benefits of early treatment and durability of treatment effect of nusinersen. No new safety concerns were identified.

Collectively, these data demonstrate that treatment with nusinersen results in continuous improvement or stabilization of disease activity for patients of all ages. Whilst the benefits are greatest with earlier treatment initiation, the SHINE data, which followed patients from the pivotal CHERISH and ENDEAR studies, also demonstrates that patients starting treatment at a later stage can still gain significant improvements in motor function and abilities that can help them in their day-to-day lives. At the time of interim analysis of SHINE, length of treatment with nusinersen was up to 474 days for patients enrolled from CHERISH and up to 592 days for those from ENDEAR.

“These data confirm the longer-term safety and efficacy profile of nusinersen and add to the impressive and growing body of clinical evidence including more than 300 patients in a broad range of ages and types of SMA,” said Ivana Rubino, Executive Medical Director and Global Head of Neuromuscular Medical Affairs at Biogen. “Over 7,500 infants, teens and adults have now been treated with nusinersen worldwide. Biogen is also continuing to help build several worldwide disease registries and real world data initiatives which will continue to deliver important long-term insights into SMA and its treatment.”

The European label update also includes data from EMBRACE which examined both infantile and later-onset SMA, final results from the CS3A study (which investigated the use of nusinersen in symptomatic patients with infantile-onset SMA) as well as data from the NURTURE study. NURTURE is an ongoing, open-label study of pre-symptomatic infants genetically diagnosed with SMA, the latest results of which are being presented at the CureSMA and EAN Congresses in the coming days.

For the full European label update please visit: https://www.ema.europa.eu/en/documents/product-information/spinraza-epar-product-information_en.pdf

About SPINRAZA® (nusinersen)1-4
Nusinersen is the first therapy approved to treat infants, children and adults with spinal muscular atrophy (SMA) and is available in more than 40 countries. As of March 31, 2019, more than 7,500 individuals have been treated with nusinersen for up to six years, based on patients across the post-marketing setting, Expanded Access Program (EAP) and clinical trial participants. Nusinersen is the only SMA treatment to combine unsurpassed real-world experience and the highest level of clinical evidence across a broad spectrum of patient populations.

SMA is a rare, genetic, neuromuscular disease that is characterized by a loss of motor neurons in the spinal cord and lower brain stem, resulting in severe, progressive muscle atrophy and weakness. Approximately one in 10,000 live births have a diagnosis of SMA and people of all ages are impacted by the disease. It is a leading genetic cause of infant mortality.

Nusinersen, a foundation of care in SMA, is an antisense oligonucleotide (ASO) designed to target a root cause of SMA by increasing the amount of full-length SMN protein, which is critical to maintaining motor neurons. It is administered by intrathecal injection into the fluid surrounding the spinal cord where motor neurons reside to deliver the treatment where the disease starts.

Nusinersen currently maintains the largest clinical data set in SMA based on data from over 300 patients across a broad range of SMA populations demonstrating a favorable benefit: risk profile. Nusinersen was evaluated in two randomized, double-blind, sham-controlled studies (ENDEAR and CHERISH) in infantile and later-onset SMA patients and supported by open label studies in pre-symptomatic infants (NURTURE) and individuals who were treated into adulthood with later-onset SMA (CS2/12). The most common adverse events observed were headache, vomiting, and back pain. Serious infections of hydrocephalus and meningitis have been observed in the post-marketing setting. Renal toxicity and coagulation abnormalities, including acute severe low platelet counts, have been observed after administration of some ASOs. Laboratory tests can monitor for these signs.

Biogen licensed the global rights to develop, manufacture and commercialize nusinersen from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), a leader in antisense therapeutics. Biogen and Ionis conducted an innovative clinical development program that moved nusinersen from its first dose in humans in 2011 to its first regulatory approval in five years.

About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – TwitterLinkedInFacebookYouTube.

Reference:

  1. Finkel, Richard S., et al. “Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.” New England Journal of Medicine, vol. 377, no. 18, 2017, pp. 1723–1732., doi:10.1056/nejmoa1702752.
  2. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell.1995;80(1):155-165.
  3. Mercuri, Eugenio, et al. “Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.” New England Journal of Medicine, vol. 378, no. 7, 2018, pp. 625–635., doi:10.1056/nejmoa1710504.
  4. Basil T. Darras, et al. “Nusinersen in later-onset spinal muscular atrophy.” Neurology, May 2019, 92 (21) e2492-e2506; DOI:10.1212/WNL.0000000000007527

MEDIA CONTACT:

Silvia Dobry
publicaffairs.eu@biogen.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Heijmans and De Wever: 220 homes in Berkel-Enschot and Tilburg12.11.2019 17:30:00 CETPress release

Heijmans and geriatric care organization De Wever, which is an organisation that provides care to the elderly, have concluded a cooperation agreement for the phased development of approximately 220 owner-occupier and rental homes in Berkel-Enschot and Tilburg. Part of the homes (112 care apartments) is intended for senior citizens with divergent care needs. The project is valued at around € 65 million. Heijmans and De Wever respond to the increasing demand for suitable homes for senior citizens in Berkel-Enschot and Tilburg by means of this cooperation. Part of the apartments is intended for senior citizens who require nursing home care. With this project Heijmans contributes to creating a healthy living environment for these target groups. The project focuses among other things on laying out indoor and outdoor spaces intended for shared use, as a result of which residents can meet each other. A new apartment complex with 52 apartments for hospital (intramural) care is being realized i

Prosafe SE: Mandatory notification of trade12.11.2019 16:09:00 CETPress release

Ryan Stewart, Chief Commercial Officer, has on 12 November 2019 purchased 45,000 shares in Prosafe SE at an average price of NOK 4.2565 per share. Following the transaction, Ryan Stewart owns 45,260 shares in Prosafe SE. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The Company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 12 November 2019 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig H. Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

SDLP - Seadrill Partners LLC Third Quarter 2019 Cash Distribution12.11.2019 15:37:00 CETPress release

London, United Kingdom, November 12, 2019 - Seadrill Partners LLC (OTCQB:SDLPF) ("Seadrill Partners" or the "Company") announces today that a distribution of $0.01 per unit has been declared with respect to the third quarter ended September 30, 2019, in line with the second quarter distribution. The third quarter cash distribution will be paid on November 27, 2019 to all unitholders of record as of the close of business on November 22, 2019. FORWARD LOOKING STATEMENTS This news release includes forward looking statements. Such statements are generally not historical in nature, and specifically include statements about the Company's plans, strategies, business prospects, changes and trends in its business and the markets in which it operates. In particular, statements regarding offshore drilling markets, the Company's ability to make cash distributions, the expected performance of the drilling units in the Company's fleet, estimated duration of customer contracts, contract dayrate amoun

DNO ASA: FAPE01 bond buyback12.11.2019 15:25:00 CETPress release

Oslo, 12 November 2019 - DNO ASA, the Norwegian oil and gas operator, today purchased USD 2.6 million in nominal value of FAPE01 bonds (ISIN NO0010811268) originally issued by Faroe Petroleum plc, and renamed DNO North Sea plc. The bonds were purchased at a price of 107.25. Following the bond buyback, USD 23.6 million in nominal value of the FAPE01 bonds remain outstanding with DNO ASA holding the balance of USD 62.2 million. The FAPE01 bonds mature on 28 April 2023. -- For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant

PCI Biotech to present at BIO-Europe 201912.11.2019 15:11:00 CETPress release

Oslo, Norway, November 12, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at BIO-Europe 2019 being held November 11-13, 2019 at Hamburg Messe, Germany. On Wednesday, November 13, 2019 at 09:15am (CET), Dr. Per Walday, CEO, will present an overview of PCI Biotech’s technology and the multiple business development and commercial opportunities available based on this proprietary platform. The presentation will be made available on PCI Biotech’s website (www.pcibiotech.com ) under “Other presentations”. About PCI Biotech PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fi